Bryan D. King

Bryan D. King

Partner

Diverse Background Experience

In addition to being a corporate partner at the firm, Bryan previously served as corporate counsel to a biopharmaceutical company and was a financial analyst in the investment banking division of Salomon Smith Barney.
Representations

Bryan has advised notable companies and investment banks such as Alpine Immune Sciences, Athira Pharma, Cloudflare, Impinj, NanoString Technologies, Xenon Pharmaceuticals, BofA Securities, Goldman Sachs, J.P. Morgan, and Morgan Stanley.

Bryan King is a partner in the Seattle office of Wilson Sonsini Goodrich & Rosati. His practice focuses on corporate and securities law matters for emerging growth companies, venture capital firms, and public companies.

Bryan was an associate in Wilson Sonsini's Seattle office from 2007 until 2011, when he joined a Seattle-area biopharmaceutical company as corporate counsel. He rejoined the firm in June 2012.

Prior to law school, Bryan was a financial analyst in the investment banking division of Salomon Smith Barney in New York, with a focus on media, telecommunications, and power companies.

Experience

Bryan was an associate in Wilson Sonsini's Seattle office from 2007 until 2011, when he joined a Seattle-area biopharmaceutical company as corporate counsel. He rejoined the firm in June 2012.

Prior to law school, Bryan was a financial analyst in the investment banking division of Salomon Smith Barney in New York, with a focus on media, telecommunications, and power companies.

Education

J.D., University of Washington School of Law, 2007With Honors, Order of the Coif
B.S.B.A., Finance, Georgetown University, 2001Cum Laude, Minor in Psychology

Admissions

State Bar of Washington

Credentials

Education

J.D., University of Washington School of Law, 2007With Honors, Order of the Coif
B.S.B.A., Finance, Georgetown University, 2001Cum Laude, Minor in Psychology

Admissions

State Bar of Washington

Select Clients

Companies represented in public offerings, private placements, mergers and acquisitions, and corporate law and governance matters include:

Alpine Immune Sciences
Apptio
Athira Pharma
Booster Fuels
Cloudflare
CTI BioPharma
DocuSign
Impinj
Isilon Systems
Kodiak Sciences
NanoString Technologies
Nintex
nLIGHT
Omeros
RealPage
Recursion Pharmaceuticals
Sarepta Therapeutics
Spotnana Technology
Xenon Pharmaceuticals
Zymeworks

Investment banks represented in public offerings include:

Barclays
BofA Securities
Credit Suisse
Goldman Sachs
Guggenheim Securities
Jefferies
J.P. Morgan
Morgan Stanley
Piper Jaffray
RBC Capital Markets
Stifel
SVB Leerink
TD Cowen

Clients

Select Clients

Companies represented in public offerings, private placements, mergers and acquisitions, and corporate law and governance matters include:

Alpine Immune Sciences
Apptio
Athira Pharma
Booster Fuels
Cloudflare
CTI BioPharma
DocuSign
Impinj
Isilon Systems
Kodiak Sciences
NanoString Technologies
Nintex
nLIGHT
Omeros
RealPage
Recursion Pharmaceuticals
Sarepta Therapeutics
Spotnana Technology
Xenon Pharmaceuticals
Zymeworks

Investment banks represented in public offerings include:

Barclays
BofA Securities
Credit Suisse
Goldman Sachs
Guggenheim Securities
Jefferies
J.P. Morgan
Morgan Stanley
Piper Jaffray
RBC Capital Markets
Stifel
SVB Leerink
TD Cowen

Recent Insights

Client Highlights

On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.

Learn More

Client Highlights

On June 17, 2025, Cloudflare, Inc. issued $2.0 billion aggregate principal amount of 0% Convertible Senior Notes due 2030. The offering amount included the exercise in full of the option that Cloudflare had granted to the initial purchasers to purchase up to an additional $250 million of notes. In connection with the offering, Cloudflare entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and other financial institutions.

Learn More

View All

Recent Events

Speaking Engagements

Join Wilson Sonsini, Deloitte, and J.P. Morgan for an exclusive webinar, “IPO Readiness 2026: The New Bar for Life Sciences & Health Care,” designed for C-suite and decision makers from life sciences and health care companies, investors, and entrepreneurs.

Learn More